publication date: Jan. 15, 2021

In Brief

Charles S. Fuchs named SVP at Roche and Genentech

Charles S. Fuchs, director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital, has been named senior vice president and global head of product development for oncology and hematology at Roche and Genentech.

Fuchs, the Richard Sackler and Jonathan Sackler Professor of Medicine and professor of chronic disease epidemiology at Yale, will start in the new role at Roche and Genentech on March 1.

“While I will greatly miss the extraordinary people of Yale Cancer Center and Smilow Cancer Hospital, my new position will allow me to continue my lifelong passion to advance scientific discovery to improve the lives of cancer patients,” Fuchs said in a statement.

Fuchs has been a member of Yale/Smilow since October 2016.


Crystal Denlinger named chief scientific officer of NCCN 

Crystal S. Denlinger was named to the new role of senior vice president and chief scientific officer of National Comprehensive Cancer Network.

In this position, Denlinger will steer strategic direction for the nonprofit and oversee the NCCN Oncology Research Program. She will also provide input into NCCN’s clinical information program, including the NCCN Clinical Practice Guidelines in Oncology, and other continuing education activities.

Denlinger holds several leadership positions with Fox Chase Cancer Center—an NCCN Member Institution—including chief of Gastrointestinal Medical Oncology; deputy director of the Early Drug Development Phase I Program; director of the Survivorship Program; and associate professor within the Department of  Hematology/Oncology.


Jonathan Weinbach named CEO of New York Proton Center

Jonathan Weinbach was named chief executive officer of the New York Proton … Continue reading Charles S. Fuchs named SVP at Roche and Genentech

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2021 The Cancer Letter Inc.